AR101 is an investigational biologic oral immunotherapy produced by Aimmune therapeutics. If that sounds like a mouthful, it is, so let’s break down what that really means. AR101 will be a commercially available “drug” with a proposed trade name of Palforzia. As such, it requires approval by the Food and Drug Administration (FDA). It is currently considered “investigational” because it has not been approved by the FDA and is still under investigation. The term “biologic” refers to a product that is isolated from natural sources and not chemically manufactured. As explained by the American Academy of Allergy, Asthma & Immunology, “oral immunotherapy (OIT) refers to feeding an allergenic individual an increasing amount of allergen with the goal of increasing the threshold that triggers a reaction.” In the case of AR101, the product is designed for peanut allergic patients and the treatment goal is to reduce the frequency and severity of allergic reactions due to accidental peanut exposure.